Association Between Erectile Dysfunction and Lower Urinary Tract Symptoms

Why This Association Matters in Clinical Practice

Every day, men over 50 walk into urology clinics with complaints that seem unrelated. Some come because they wake up three times at night to urinate. Others come because they cannot achieve or maintain an erection. Often, these men do not connect the two problems. They see one as a “bladder issue” and the other as a “performance issue.” But the medical literature tells a different story: erectile dysfunction and lower urinary tract symptoms frequently coexist, and their shared pathophysiology has been recognized for decades.

The biological link between erectile dysfunction and LUTS involves several mechanisms. Reduced nitric oxide bioavailability affects both cavernosal smooth muscle relaxation (erection) and bladder neck/prostate smooth muscle tone (voiding). Sympathetic nervous system overactivity contributes to both increased prostatic resistance and vasoconstriction of penile arteries. Pelvic atherosclerosis reduces blood flow to both the prostate and the penis. Endothelial dysfunction, often driven by hypertension, diabetes, and hyperlipidemia, damages blood vessels throughout the pelvic region.

However, most of the published data on this association come from Western populations, and data from South Asia remain limited. This matters because genetic background, diet, lifestyle, healthcare access, and cultural factors may influence both the prevalence and the strength of the association.

The study by Gyani and colleagues (2025) addresses this gap. Conducted at King George’s Medical University in Lucknow, India, this cross-sectional study examined the relationship between ED and LUTS in 183 men aged 50 years or older presenting with benign prostatic hyperplasia or lower urinary tract symptoms. The full text is available here: cross-sectional study by Gyani and colleagues (2025)

Study Design: A Cross-Sectional Approach

This study is not a clinical trial. There was no intervention, no treatment assignment, and no control group in the sense of a placebo or active comparator. Instead, the investigators enrolled consecutive patients who presented to a tertiary care hospital in North India with either LUTS or known BPH. All participants were then assessed at a single time point.

Inclusion criteria: Men aged 50 years or older with LUTS or BPH. No exclusion criteria are specified in the abstract, but full-text details would include conditions such as prostate cancer, previous prostate surgery, or neurological disorders affecting bladder function.

Sample size: 183 men.

Statistical analysis: Correlation analysis (Pearson or Spearman depending on data distribution). Significance set at p < 0.05.

Patient Characteristics and Distribution

The average age of participants was 63.13 years (standard deviation 8.98). This is typical for a BPH/LUTS population, as symptoms rarely become bothersome before age 50 and increase in prevalence with each decade.

The distribution of LUTS severity among the 183 men is shown below. Notably, nearly two-thirds of patients had moderate or severe symptoms, reflecting the tertiary care setting where patients with more bothersome symptoms seek specialized care.

The distribution of erectile dysfunction severity shows that only a small minority of men had normal or only mild ED. The majority had moderate or severe dysfunction.

Clinical interpretation: Only 9.8% of men presenting with LUTS or BPH had severe ED based on IIEF-15 scoring. This is actually lower than some Western studies, which have reported severe ED rates of 15-25% in similar populations. However, direct comparisons are difficult because IIEF-15 thresholds for severity categories vary between studies. More important than the absolute percentages is the pattern: as LUTS severity increased, ED severity also increased.

Key Correlations Found

The study identified several statistically significant associations.

Age and ED. There was a strong correlation between increasing age and worsening erectile dysfunction (p < 0.001). This is expected and consistent with decades of epidemiological research. Aging affects every component of erectile function: vascular health, nerve function, hormone levels, and psychological state.

LUTS severity and ED. Higher IPSS scores (worse lower urinary tract symptoms) were significantly correlated with lower IIEF-15 scores (worse erectile function), with p < 0.05. This is the core finding of the study. For the practicing urologist, this means that a man who reports severe urinary symptoms (frequent urination, urgency, weak stream) is statistically more likely to also have significant erectile dysfunction, even if he does not volunteer that information.

Testosterone and ED. IIEF-15 scores showed a significant positive correlation with serum testosterone levels (r = 0.679, p < 0.001). A correlation coefficient of 0.679 is considered strong (close to 1.0). This means that men with lower testosterone had substantially worse erectile function. Importantly, correlation does not prove causation – low testosterone could cause ED, ED could cause psychological stress that lowers testosterone, or a third factor (e.g., chronic illness) could lower both. However, the strength of the association suggests that checking testosterone in men with LUTS and ED is clinically useful.

PSA and ED. No significant correlation was found between PSA levels and ED severity. This is also expected. PSA is a marker of prostate epithelial activity, influenced by prostate volume, inflammation, infection, and cancer. There is no biological reason to expect it to correlate with erectile function, which is determined by vascular, neural, and hormonal factors.

Comorbidities and ED. Both hypertension and diabetes mellitus were significantly associated with ED (p < 0.05 for each). This confirms what is already well known: these metabolic and vascular conditions damage the endothelium, reduce nitric oxide availability, and impair the ability of penile arteries to dilate adequately during sexual arousal.

Two Key Takeaways from the Gyani Study

• The severity of lower urinary tract symptoms correlates significantly with the severity of erectile dysfunction in North Indian men with BPH. This finding mirrors what has been reported in Western and East Asian populations, suggesting that the ED-LUTS association is robust across different genetic and environmental backgrounds. For the clinician, this means that a patient with a high IPSS score (moderate or severe LUTS) is statistically likely to have underlying erectile dysfunction, regardless of whether he complains about it.
• Serum testosterone levels show a strong positive correlation with erectile function (r = 0.679, p < 0.001), while PSA levels show no correlation. This has direct clinical utility. When evaluating a man with LUTS who also has or is at risk for ED, measuring morning total testosterone provides clinically actionable information. A low testosterone level may explain a poor response to PDE5 inhibitors or may indicate the need for testosterone replacement therapy. In contrast, checking PSA in the absence of other indications (family history, abnormal digital rectal exam) does not help assess erectile dysfunction.

Limitations of the Study – A Different Perspective

This is not an interventional study, so its limitations are of a different nature than those of the randomized trials discussed in previous articles.

Clinical Interpretation for the Practicing Urologist

Despite these limitations, the Gyani study reinforces several principles that can be applied immediately in clinical practice.

Systematic screening for ED in men with LUTS is underutilized. In this study, nearly 50% of men presenting with LUTS had moderate or severe ED when formally assessed with the IIEF-15. Many of these men likely did not volunteer their erectile complaints during the initial consultation. A simple, validated questionnaire such as the IIEF-5 (the 5-item version) takes less than two minutes to complete and can be administered in the waiting room.

Testosterone measurement should be routine in this population. The correlation coefficient of 0.679 indicates that testosterone level is one of the strongest correlates of erectile function in this study, stronger than age or IPSS score. For any man with LUTS who reports ED or who screens positive on the IIEF-5, checking morning total testosterone is a low-cost, high-yield test.

PSA is not a marker for erectile dysfunction. The absence of correlation between PSA and IIEF-15 confirms that PSA should be used only for its intended purpose: assessing prostate cancer risk. Ordering a PSA because a man has ED is not evidence-based. Conversely, a man with a normal PSA may still have severe ED requiring treatment.

Comorbidities require active management. The significant association of hypertension and diabetes with ED in this study is not new, but it bears repeating. Optimizing blood pressure control (avoiding beta-blockers as first-line agents when possible) and achieving good glycemic control may improve erectile function, although this was not tested in the study. Referral to a primary care physician or endocrinologist is often necessary.

What This Study Does Not Tell Us

The Gyani study is descriptive, not prescriptive. It does not tell us whether treating LUTS improves ED or whether treating ED improves LUTS. It does not compare different treatment strategies (alpha-blockers vs PDE5 inhibitors vs combination therapy). It does not provide data on long-term outcomes or on patient satisfaction with treatment.

For answers to these questions, we must look to interventional studies randomized controlled trials such as the Taha trial (tadalafil after TURP) or meta-analyses such as Quistini (combination PDE5i plus LiSWT). The Gyani study provides context: it confirms that the two conditions are indeed linked in the population, which justifies efforts to develop and test dual-effect treatments.

Application in Our Practice

At Adult & Pediatric Urology (APUMN), we use the findings of this cross-sectional study to structure our initial evaluation of men over 50 who present with lower urinary tract symptoms. All such patients complete the IPSS for LUTS and the IIEF-5 for erectile dysfunction while in the waiting room, regardless of whether they mention sexual complaints. For patients with moderate-to-severe ED (IIEF-5 ≤ 16), we include morning total testosterone measurement in the initial laboratory panel. PSA is ordered only when clinically indicated by age, family history, or abnormal digital rectal examination, not as part of an ED workup. This systematic approach, supported by epidemiological studies like Gyani et al., helps identify treatable contributors to ED particularly hypogonadism that might otherwise be missed when the clinical focus is entirely on the prostate.

Conclusion for Clinicians and Patients

The study by Gyani and colleagues adds to the substantial body of evidence showing that erectile dysfunction and lower urinary tract symptoms are not separate, unrelated conditions in aging men. They share biological mechanisms, risk factors, and clinical presentations. A man with severe LUTS is likely to have at least moderate ED, even if he does not mention it. A man with low testosterone is likely to have both worse LUTS and worse ED.

For clinicians, the take-home message is simple: look for what you are not being told. Screen all men over 50 with LUTS for erectile dysfunction. Measure testosterone in those who screen positive. Treat comorbidities aggressively. And remember that PSA has no role in the assessment of ED.

For patients, the message is equally simple: if you are having trouble with urination and also having trouble with erections, tell your doctor about both. They are connected. And there are effective treatments from lifestyle changes and testosterone replacement to PDE5 inhibitors and, in selected cases, minimally invasive procedures. You do not have to live with either condition, and treating one may help the other.

Author

Jerome P. Keating, M.D